Thursday, November 19, 2026

Dissociable afferent and cortical physiological contributions to motor disability in Friedreich ataxia: an integrated MEG study

Georgiev Christian, Bourguignon Mathieu, Cabaraux Pierre, Digileva Daria, Naeije Gilles, Dissociable afferent and cortical physiological contributions to motor disability in Friedreich ataxia: an integrated MEG study, Clinical Neurophysiology, 2026, 2112477, ISSN 1388-2457, doi:10.1016/j.clinph.2026.2112477. 

This study demonstrates that complementary afferent and cortical physiological abnormalities in FRDA can be non-invasively quantified within individuals. These MEG-derived measures provide a physiological framework for investigating disease heterogeneity and candidate biomarkers for monitoring disease progression and therapeutic interventions.

Tuesday, November 17, 2026

Neuroimmune transcriptional signatures across repeat expansion ataxias in the human brain

Chen, Z., Hicks, A.R., Brenton, J. et al. Neuroimmune transcriptional signatures across repeat expansion ataxias in the human brain. Acta Neuropathol 152, 70 (2026). doi:10.1007/s00401-026-03115-1 

 We identify immune and inflammatory activation as a recurring molecular feature of disease and highlight the contribution of non-neuronal cell populations to the ataxia disease state. These findings extend current understanding of repeat expansion disorders and suggest that immune-related pathways may represent shared components of disease biology across genetically distinct ataxias and potential targets for therapeutic intervention. Continued investigation of these processes in human tissue and experimental models will be important for clarifying their role in disease initiation and progression and for determining whether modulation of immune responses may represent a viable therapeutic strategy in hereditary ataxia.

Targeting Nrf2 Signaling in Friedreich’s Ataxia Cardiomyopathy: Sex-Dependent Therapeutic Responses to Dimethyl Fumarate and Omaveloxolone

Figueroa, F.; Salinas, L.; Montgomery-Bowie, C.B.; Sellers, R.; Sims, L.; Cox, G.P.; Golove, S.L.; Thai, P.N.; Chiamvimonvat, N.; Cortopassi, G.; et al. Targeting Nrf2 Signaling in Friedreich’s Ataxia Cardiomyopathy: Sex-Dependent Therapeutic Responses to Dimethyl Fumarate and Omaveloxolone. Antioxidants 2026, 15, 1490. doi:10.3390/antiox15111490 

 DMF partially improved cardiac function in males, increasing stroke volume, enhancing metabolic flexibility, and restoring mitochondrial enzyme activity; however, diastolic dysfunction persisted. OMAV treatment was associated with female-specific electrophysiological abnormalities, including increased arrhythmic burden and reduced J-wave amplitude, with persistent fibrotic remodeling. Both treatments attenuated region-specific cardiomyocyte atrophy in FXNKD males and females. These findings suggest that Nrf2 activation alone is insufficient to reverse FA-associated cardiomyopathy and reveal sex-dependent therapeutic responses. Further investigation of complementary treatment strategies may help address persistent cardiac dysfunction and remodeling in FA.

Monday, November 16, 2026

EE497 Healthcare and Economic Impact of Friedreich's Ataxia in Italy: A Stratified Analysis Based On Patients’ Ambulatory Status

Ippazio Cosimo Antonazzo, Paolo Angelo Cortesi, Lorenzo G. Mantovani, Richard Lawson, Leila Khader, Claudia Oliviero, Laura Santoni, Antonio Cittadini, Gabriella Paparella, Francesco Saccà, EE497 Healthcare and Economic Impact of Friedreich's Ataxia in Italy: A Stratified Analysis Based On Patients’ Ambulatory Status, Value in Health, Volume 28, Issue 12, Supplement 1, 2025, Pages S203-S204, ISSN 1098-3015, doi:10.1016/j.jval.2025.09.879. 

 Loss of ambulation increases FA patient management costs from both NHS and societal perspectives.

Omaveloxolone functions as a molecular crowbar-like degrader of STING to alleviate aging-related inflammation

Zhou, J., Ma, X., Jiang, B. et al. Omaveloxolone functions as a molecular crowbar-like degrader of STING to alleviate aging-related inflammation. Nat Commun 17, 11202 (2026). doi:10.1038/s41467-026-77760-1 

Aberrant activation of the STING signaling pathway is involved with aging-related inflammation, yet no STING-targeting therapeutics are clinically approved. Here, we identify Omaveloxolone, an FDA-approved drug for Friedreich’s ataxia, as a potent STING degrader (DC50 = 118 nM, Dmax = 98.6%) via high-throughput screening. 

This study implicates Omaveloxolone as a molecular crowbar-like STING degrader and provides a mechanistic framework for targeting STING via conformational perturbation.

Larimar Narrows Q3 Loss; Completes BLA Submission For Nomlabofusp In Friedreich's Ataxia

Published: 11/16/2026. Larimar completed its rolling BLA submission to the U.S. Food and Drug Administration (FDA), seeking accelerated approval of nomlabofusp for adults and pediatric patients with Friedreich's ataxia. The application uses frataxin (FXN) as a potential novel surrogate endpoint.

BLA submission acceptance is expected in early 2027. An open-label study safety update is anticipated in the first quarter of 2027, followed by a potential U.S. approval in mid-2027, subject to FDA review. 

 If approved, Larimar is targeting a U.S. commercial launch in the third quarter of 2027. The company also expects to obtain and monetize a Rare Pediatric Disease Priority Review Voucher in mid-2027, if nomlabofusp receives approval.

Sunday, November 15, 2026

FXN protomutations are the source of pathogenic expanded GAA alleles in Friedreich ataxia and explain its unequal population distribution

Devore MC, Lam C, Xiao E, Devore J, McCain KRC, Wiley G, Park CC, Lynch DR, Bidichandani SI. FXN protomutations are the source of pathogenic expanded GAA alleles in Friedreich ataxia and explain its unequal population distribution. Hum Mol Genet. 2026 Jun 9;35(11):ddag046. doi: 10.1093/hmg/ddag046. PMID: 42262226; PMCID: PMC13248553. 

 These data indicate that FXN protomutations serve as a reservoir for the generation of premutation and E alleles, and for millennia have sustained the geographically-defined population distribution of FRDA.

Integration of Evolutionary Analysis With RFdiffusion for De Novo Design of Aggregation-Resistant Frataxin

Kırboğa KK, Küçüksille EU. Integration of Evolutionary Analysis With RFdiffusion for De Novo Design of Aggregation-Resistant Frataxin. Proteins. 2026 Jun;94(6):1225-1244. doi: 10.1002/prot.70114. Epub 2026 Jan 21. PMID: 41563298. 

 This work establishes a generalizable framework for therapeutic protein engineering where backbone redesign enables conformational ensemble modulation beyond the limitations of sequence optimization alone.

Nerve ultrasound as a biomarker in Friedreich’s ataxia

Giuseppe Di Pietro, Ettore Cioffi, Pietro Falco, Caterina Leone, Giulia Di Stefano, Eleonora Galosi, Gianfranco De Stefano, Valentina Martinez, Stefano Perotti, Carlo Casali, Andrea Truini,, PO 286 Nerve ultrasound as a biomarker in Friedreich’s ataxia, Clinical Neurophysiology, Volume 185, 2026, 2111295, ISSN 1388-2457, doi:10.1016/j.clinph.2025.2111295. 

 All patients exhibited severe sensory axonal neuropathy. HRUS showed significant CSA enlargement in the median and ulnar nerves at the axilla and upper arm. The number of affected nerve sites correlated directly with disability scores (SARA, FARS, mFARS, ADL 0-36, INCAT) and inversely with IADL.

Sex-based differences in the NRF2 oxidative stress response: Implications for precision therapeutics

Giusy Russomanno, Karolina Kwiatkowska, Ian M. Copple, Sex-based differences in the NRF2 oxidative stress response: Implications for precision therapeutics, Redox Biology, Volume 92, 2026, 104128, ISSN 2213-2317, doi:10.1016/j.redox.2026.104128. 

 Hormonal status, age, and tissue-specific receptor distribution further modulate these effects, suggesting that therapeutic responses to NRF2 activators are inherently sex-dependent. Pharmacokinetic and pharmacodynamic differences, including CYP3A-mediated metabolism and body composition, may additionally influence systemic exposure and safety profiles. Despite clinical use of NRF2 activators such as dimethyl fumarate and omaveloxolone, sex-stratified data on efficacy, dosing, and safety are scarce. This knowledge gap underscores the need for systematic evaluation of sex, hormonal milieu, and age in pharmacokinetic, pharmacodynamic, and clinical studies to ensure treatments are safe, effective, and equitable. Integrating these variables into research and clinical practice will optimise therapeutic benefits and minimise adverse events by accounting for patient-specific biology.